FDA Instability Is Changing Biotech Investment—What Investors Are Saying
FDA instability is reshaping biotech investment decisions in real time. Investors are recalibrating risk, pulling back, and even shifting capital abroad.
In this episode of the Making Medicine Podcast, John Stanford is joined by Rachel Sher of Manatt Health to unpack new original research conducted with investors across the biotech ecosystem. The goal was simple: move beyond speculation and understand whether recent leadership changes, staffing cuts, and policy uncertainty at FDA are actually shaping investor behavior.
What emerged is a clear signal. Across venture capital, public equity…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.